AstraZeneca Buying Novaxel For Up To $425 Million
AstraZeneca has agreed to acquire Novexel, a French infection research company. The deal includes a $375 million up-front cash payment, plus up to $75 million in milestone payments. Novexel has raised around $127 million in VC funding since 2004, from firms like Atlas Venture, Abingworth Management, 3i Group, Goldman Sachs, Sofinnova Partners, Edmond de Rothschild Investment Partners, 123Venture, Daiwa SMBC Capital and Novo AS.
23 December 2009•5 mins read
